Trevi Therapeutics reported a net loss of $11.4 million for the fourth quarter of 2024, compared to a net loss of $7.8 million in the same period of 2023. For the full year 2024, the net loss was $47.9 million, an increase from $29.1 million in 2023.
Research and development (R&D) expenses for Q4 2024 increased to $9.3 million from $6.5 million, and for the full year, they rose to $39.4 million from $23.7 million in 2023. General and administrative (G&A) expenses also increased to $2.9 million in Q4 2024 and $12.1 million for the full year.
The company ended 2024 with $107.6 million in cash, cash equivalents, and marketable securities, with an expected cash runway into the second half of 2026. These financial results were accompanied by updates on positive topline data from the Phase 2a RIVER trial, completion of enrollment in the Phase 2b CORAL trial, and a positive outcome from the CORAL trial's sample size re-estimation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.